Literature DB >> 2169989

Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions.

S Masood1, E R Frykberg, G L McLellan, M C Scalapino, D G Mitchum, J B Bullard.   

Abstract

The application of fine-needle aspiration biopsy (FNAB) to the diagnosis of nonpalpable breast lesions was evaluated with a new method which uses standard needle localization under mammographic guidance to assure accurate sampling by FNAB. This method was prospectively applied to 100 mammographically detected breast lesions in 100 women (mean age, 53 years). All 100 patients underwent surgical excision of these nonpalpable lesions after cytologic aspiration. Sufficient aspirated material was obtained for cytologic diagnosis from 91 patients (91%). The histologic and cytologic interpretations were then compared. Twenty malignancies were ultimately diagnosed by histology (12 invasive ductal carcinoma, six ductal carcinoma in situ, and two lobular carcinoma in situ), of which 17 had been cytologically diagnosed. There were no false-positive diagnoses of malignancy by FNAB. False-negative readings (3.3%) included two cases of lobular carcinoma in situ and one case of ductal carcinoma in situ. This technique thus demonstrated a sensitivity of 85%, specificity of 100%, and overall diagnostic accuracy of 96.7% for the nonsurgical detection of malignancy in nonpalpable breast lesions. These results suggest that the established safety, reliability, and cost-effectiveness of FNAB can be maintained in this clinical setting. This procedure may obviate the need for open surgical biopsy in those patients with an unequivocal diagnosis of malignancy. It can also be done using standard techniques and equipment available in many community hospitals.

Entities:  

Mesh:

Year:  1990        PMID: 2169989     DOI: 10.1002/1097-0142(19901001)66:7<1480::aid-cncr2820660708>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  A Case of Ductal Carcinoma In Situ (DCIS:noncomedo type)Detected by Ultrasonography: Demonstration of Occult Multiple Foci.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

2.  Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial.

Authors:  Seema A Khan; Robert T Chatterton; Nancy Michel; Michelle Bryk; Oukseub Lee; David Ivancic; Richard Heinz; Carola M Zalles; Irene B Helenowski; Borko D Jovanovic; Adrian A Franke; Maarten C Bosland; Jun Wang; Nora M Hansen; Kevin P Bethke; Alexander Dew; Margerie Coomes; Raymond C Bergan
Journal:  Cancer Prev Res (Phila)       Date:  2012-02

3.  Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside.

Authors:  Carol J Fabian; Bruce F Kimler; Carola M Zalles; Jennifer R Klemp; Brian K Petroff; Qamar J Khan; Priyanka Sharma; Kenneth D R Setchell; Xueheng Zhao; Teresa A Phillips; Trina Metheny; Jennifer R Hughes; Hung-Wen Yeh; Karen A Johnson
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-19

4.  Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women.

Authors:  Carol J Fabian; Bruce F Kimler; Teresa A Phillips; Jennifer L Nydegger; Amy L Kreutzjans; Susan E Carlson; Brandon H Hidaka; Trina Metheny; Carola M Zalles; Gordon B Mills; Kandy R Powers; Debra K Sullivan; Brian K Petroff; Whitney L Hensing; Brooke L Fridley; Stephen D Hursting
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

5.  A case of solitary intraductal papilloma of the breast coexisting with ductal carcinoma in situ (DCIS).

Authors:  Nobuyuki Takemoto; Hiroshi Yamamoto; Katsuko Shiraishi; Junko Koike
Journal:  J Med Ultrason (2001)       Date:  2007-03-15       Impact factor: 1.314

6.  Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.

Authors:  Carol J Fabian; Bruce F Kimler; Carola M Zalles; Teresa A Phillips; Trina Metheny; Brian K Petroff; Thomas C Havighurst; KyungMann Kim; Howard H Bailey; Brandy M Heckman-Stoddard
Journal:  Cancer Prev Res (Phila)       Date:  2015-09-21

7.  Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women.

Authors:  Carol J Fabian; Bruce F Kimler; Teresa A Phillips; Jessica A Box; Amy L Kreutzjans; Susan E Carlson; Brandon H Hidaka; Trina Metheny; Carola M Zalles; Gordon B Mills; Kandy R Powers; Debra K Sullivan; Brian K Petroff; Whitney L Hensing; Brooke L Fridley; Stephen D Hursting
Journal:  Cancer Prev Res (Phila)       Date:  2015-10

Review 8.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

9.  ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Authors:  Joseph C Baker; Julie H Ostrander; Siya Lem; Gloria Broadwater; Gregory R Bean; Nicholas C D'Amato; Vanessa K Goldenberg; Craig Rowell; Catherine Ibarra-Drendall; Tracey Grant; Patrick G Pilie; Shauna N Vasilatos; Michelle M Troch; Victoria Scott; Lee G Wilke; Carolyn Paisie; Sarah M Rabiner; Alejandro Torres-Hernandez; Carola M Zalles; Victoria L Seewaldt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

10.  Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study.

Authors:  Catherine Ibarra-Drendall; Lee G Wilke; Carola Zalles; Victoria Scott; Laura E Archer; Siya Lem; Lisa D Yee; Joanne Lester; Swati Kulkarni; Christine Murekeyisoni; Marie Wood; Karen Wilson; Judy Garber; Carleen Gentry; April Stouder; Gloria Broadwater; Joseph C Baker; Shauna N Vasilatos; Elizabeth Owens; Sarah Rabiner; Abbey C Barron; Victoria L Seewaldt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.